Cargando…

Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.

Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36 primary breast carcinomas. Using monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, S., Duffy, M. J., Duggan, C., Barnes, C., Rafferty, R., Kramer, M. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150065/
https://www.ncbi.nlm.nih.gov/pubmed/9635840
_version_ 1782144566264070144
author Kennedy, S.
Duffy, M. J.
Duggan, C.
Barnes, C.
Rafferty, R.
Kramer, M. D.
author_facet Kennedy, S.
Duffy, M. J.
Duggan, C.
Barnes, C.
Rafferty, R.
Kramer, M. D.
author_sort Kennedy, S.
collection PubMed
description Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36 primary breast carcinomas. Using monoclonal antibody HD-UK 1, uPA was detected both in stromal and in malignant cells. However, the predominant location was in the stromal cells. Using double-staining, cells containing uPA were also found to coexpress either cytokeratin (an epithelial cell marker) or more frequently KP1 (a macrophage/monocyte cell marker). With monoclonal antibody HD-uPAR 13.1, uPAR was localized principally to spindle- or macrophage-like stromal cells, especially when these cells surrounded invasive breast cancer. In contrast, uPAR was only rarely detected in cancer cells and was not detected in normal epithelia surrounding tumour or in areas of adenosis. uPA levels in both stromal and epithelial cells were significantly correlated with those for uPAR. We conclude that both uPA and its receptor are mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to mediate metastasis. IMAGES:
format Text
id pubmed-2150065
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21500652009-09-10 Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Kennedy, S. Duffy, M. J. Duggan, C. Barnes, C. Rafferty, R. Kramer, M. D. Br J Cancer Research Article Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36 primary breast carcinomas. Using monoclonal antibody HD-UK 1, uPA was detected both in stromal and in malignant cells. However, the predominant location was in the stromal cells. Using double-staining, cells containing uPA were also found to coexpress either cytokeratin (an epithelial cell marker) or more frequently KP1 (a macrophage/monocyte cell marker). With monoclonal antibody HD-uPAR 13.1, uPAR was localized principally to spindle- or macrophage-like stromal cells, especially when these cells surrounded invasive breast cancer. In contrast, uPAR was only rarely detected in cancer cells and was not detected in normal epithelia surrounding tumour or in areas of adenosis. uPA levels in both stromal and epithelial cells were significantly correlated with those for uPAR. We conclude that both uPA and its receptor are mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to mediate metastasis. IMAGES: Nature Publishing Group 1998-05 /pmc/articles/PMC2150065/ /pubmed/9635840 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kennedy, S.
Duffy, M. J.
Duggan, C.
Barnes, C.
Rafferty, R.
Kramer, M. D.
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title_full Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title_fullStr Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title_full_unstemmed Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title_short Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
title_sort semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150065/
https://www.ncbi.nlm.nih.gov/pubmed/9635840
work_keys_str_mv AT kennedys semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry
AT duffymj semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry
AT dugganc semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry
AT barnesc semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry
AT raffertyr semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry
AT kramermd semiquantitationofurokinaseplasminogenactivatoranditsreceptorinbreastcarcinomasbyimmunocytochemistry